Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osocimab in ESRD patients on hemodialysis
NCT03787368Phase 1Completed
- Sponsor
- Bayer
- Start
- Jan 2019
- Primary completion
- Sep 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, single-blind trial of osocimab in thromboembolism, sponsored by Bayer. Primary endpoint: Number of major and CRNM bleeding events. Started Jan 2019; status: completed.
02
Drugs
osocimab
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT03787368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03787368.